{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:55:29Z","timestamp":1790420129751,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001631","name":"University College Dublin","doi-asserted-by":"publisher","award":["No.82934-NP\/R27885"],"award-info":[{"award-number":["No.82934-NP\/R27885"]}],"id":[{"id":"10.13039\/501100001631","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005671","name":"FAPITEC\/SE","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Pathogenesis and Therapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.cpt.2024.10.001","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T07:58:25Z","timestamp":1730102305000},"page":"322-336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["An overview of randomized phase III clinical trials of cancer nanomedicines"],"prefix":"10.1016","volume":"3","author":[{"given":"Micael N.","family":"Melo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo G.","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8866-2030","authenticated-orcid":false,"given":"Lucas R.","family":"Melo de Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Severino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Blanco-Llamero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana N.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9737-6017","authenticated-orcid":false,"given":"Eliana B.","family":"Souto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpt.2024.10.001_bib1","doi-asserted-by":"crossref","first-page":"8606","DOI":"10.1039\/D2RA07863E","article-title":"Cancer nanomedicine: a review of nano-therapeutics and challenges ahead","volume":"13","author":"Nirmala","year":"2023","journal-title":"RSC Adv"},{"key":"10.1016\/j.cpt.2024.10.001_bib2","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.cpt.2024.10.001_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.rvsc.2018.12.002","article-title":"Properties of capsaicin and its utility in veterinary and human medicine","volume":"123","author":"Adaszek","year":"2019","journal-title":"Res Vet Sci"},{"key":"10.1016\/j.cpt.2024.10.001_bib4","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4927312","article-title":"Cancer nanomedicine: a new era of successful targeted therapy","volume":"2019","author":"El-Readi","year":"2019","journal-title":"J Nanomater"},{"key":"10.1016\/j.cpt.2024.10.001_bib5","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/molecules23040826","article-title":"Nanotechnology for cancer therapy based on chemotherapy","volume":"23","author":"Zhao","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.cpt.2024.10.001_bib6","doi-asserted-by":"crossref","first-page":"5719","DOI":"10.2147\/IJN.S254774","article-title":"Past, present, and future of anticancer nanomedicine","volume":"15","author":"Kim","year":"2020","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.cpt.2024.10.001_bib7","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3390\/pharmaceutics12111028","article-title":"Timeline of translational formulation technologies for cancer therapy: successes, failures, and lessons learned therefrom","volume":"12","author":"P\u00e9rez-L\u00f3pez","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cpt.2024.10.001_bib8","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpt.2024.10.001_bib9","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/abaadb","article-title":"Roadmap on nanomedicine","volume":"32","author":"Decuzzi","year":"2021","journal-title":"Nanotechnology"},{"key":"10.1016\/j.cpt.2024.10.001_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2217\/nnm-2018-0120","article-title":"Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities","volume":"14","author":"Farjadian","year":"2019","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.cpt.2024.10.001_bib11","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.3390\/cancers11121855","article-title":"Thirty years of cancer nanomedicine: success, frustration, and hope","volume":"11","author":"Salvioni","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.cpt.2024.10.001_bib12","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.3390\/molecules25092193","article-title":"Therapeutic nanoparticles and their targeted delivery applications","volume":"25","author":"Yetisgin","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.cpt.2024.10.001_bib13","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jconrel.2021.04.028","article-title":"(Poly-cyanoacrylate) nanomedicines for cancer and beyond: lessons learned","volume":"334","author":"Couvreur","year":"2021","journal-title":"J Contr Release"},{"key":"10.1016\/j.cpt.2024.10.001_bib14","first-page":"10","article-title":"Nanoparticle-based drug delivery systems for cancer therapy","volume":"1","author":"Dang","year":"2020","journal-title":"Smart Mater Med"},{"key":"10.1016\/j.cpt.2024.10.001_bib15","article-title":"Evolution of artificial intelligence as a modern technology in advanced cancer therapy","volume":"98","author":"Khan","year":"2024","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.cpt.2024.10.001_bib16","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1056\/NEJMoa2215145","article-title":"Hydrocortisone in severe community-acquired pneumonia","volume":"388","author":"Dequin","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpt.2024.10.001_bib17","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.2217\/nnm-2018-0122","article-title":"Nucleic acid nanomedicines in Phase II\/III clinical trials: translation of nucleic acid therapies for reprogramming cells","volume":"13","author":"Herrera","year":"2018","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.cpt.2024.10.001_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1497","article-title":"A hindsight reflection on the clinical studies of poly(l-glutamic acid)-paclitaxel","volume":"10","author":"Zhao","year":"2018","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"10.1016\/j.cpt.2024.10.001_bib19","doi-asserted-by":"crossref","first-page":"8423","DOI":"10.1021\/acsnano.8b03900","article-title":"Quantifying the ligand-coated nanoparticle delivery to cancer cells in solid tumors","volume":"12","author":"Dai","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.cpt.2024.10.001_bib20","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1158\/1078-0432.CCR-20-1041","article-title":"Efficacy and safety exposure-response relationships of apalutamide in patients with nonmetastatic castration-resistant prostate cancer","volume":"26","author":"Perez-Ruixo","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpt.2024.10.001_bib21","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdz397","article-title":"Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer","volume":"30","author":"Small","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib22","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpt.2024.10.001_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2024.04.010","article-title":"Regulatory insights into nanomedicine and gene vaccine innovation: safety assessment, challenges, and regulatory perspectives","volume":"180","author":"Souto","year":"2024","journal-title":"Acta Biomater"},{"key":"10.1016\/j.cpt.2024.10.001_bib24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.nantod.2019.02.005","article-title":"Clinical cancer nanomedicine","volume":"25","author":"Wolfram","year":"2019","journal-title":"Nano Today"},{"key":"10.1016\/j.cpt.2024.10.001_bib25","article-title":"Advanced bioanalytic techniques for pharmacokinetic studies of nanocarrier drug delivery systems","author":"Meng","year":"2024","journal-title":"J Pharm Anal"},{"key":"10.1016\/j.cpt.2024.10.001_bib26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejpb.2018.04.003","article-title":"Pharmacokinetics of lipid-drug conjugates loaded into liposomes","volume":"128","author":"Signorell","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.cpt.2024.10.001_bib27","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12916-017-0910-9","article-title":"Ethics review in compassionate use","volume":"15","author":"Borysowski","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.cpt.2024.10.001_bib28","article-title":"Nanomedicine in action: an overview of cancer nanomedicine on the market and in clinical trials","volume":"2013","author":"Wang","year":"2013","journal-title":"J Nanomater"},{"key":"10.1016\/j.cpt.2024.10.001_bib29","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.2217\/fon-2017-0247","article-title":"A review of BF-200 ALA for the photodynamic treatment of mild-to-moderate actinic keratosis","volume":"13","author":"Reinhold","year":"2017","journal-title":"Future Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib30","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2217\/nnm-2018-0313","article-title":"Nanopaclitaxel therapy: an evidence based review on the battle for next-generation formulation challenges","volume":"14","author":"Barkat","year":"2019","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.cpt.2024.10.001_bib31","first-page":"53","article-title":"Nanotechnology in cancer: an overview on importance of patient\u2019s screening in nanomedicine based combinational therapies","volume":"1","author":"Sarma","year":"2018","journal-title":"Arch Nanomed Open Access J"},{"key":"10.1016\/j.cpt.2024.10.001_bib32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3109\/10428199309149129","article-title":"L-asparaginase and PEG asparaginase--past, present, and future","volume":"10","author":"Keating","year":"1993","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cpt.2024.10.001_bib33","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib34","doi-asserted-by":"crossref","first-page":"7768","DOI":"10.1200\/JCO.2005.08.002","article-title":"Nanoparticle albumin-bound paclitaxel for metastatic breast cancer","volume":"23","author":"Harries","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib35","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2217\/14796694.1.6.755","article-title":"Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer","volume":"1","author":"Moreno-Aspitia","year":"2005","journal-title":"Future Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib36","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","article-title":"Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial","volume":"29","author":"Von Hoff","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib37","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO.1995.13.7.1777","article-title":"Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies","volume":"13","author":"Uziely","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib38","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.1998.16.7.2445","article-title":"Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial","volume":"16","author":"Northfelt","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib39","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3816\/CLM.2007.n.001","article-title":"Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma","volume":"7","author":"Manochakian","year":"2007","journal-title":"Clinical Lymphoma & Myeloma"},{"key":"10.1016\/j.cpt.2024.10.001_bib40","doi-asserted-by":"crossref","first-page":"13388","DOI":"10.1002\/cam4.6041","article-title":"Pegylated liposomal doxorubicin (PLD) in daily practice\u2014a single center experience of treatment with PLD in patients with comorbidities and older patients with metastatic breast cancer","volume":"12","author":"Wallrabenstein","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.cpt.2024.10.001_bib41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0169-409X(97)00054-9","article-title":"Therapeutic effects of leuprorelin microspheres in prostate cancer","volume":"28","author":"Sharifi","year":"1997","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.cpt.2024.10.001_bib42","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/jnci\/81.12.935","article-title":"Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide","volume":"81","author":"MacEwen","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cpt.2024.10.001_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2022.101512","article-title":"Nanoparticle-based medicines in clinical cancer therapy","volume":"45","author":"Wang","year":"2022","journal-title":"Nano Today"},{"key":"10.1016\/j.cpt.2024.10.001_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154993","article-title":"Current status and prospects for improved targeted delivery approaches for cancer","volume":"253","author":"Mansouri","year":"2024","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.cpt.2024.10.001_bib45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0090-4295(02)02396-8","article-title":"Eligard: leuprolide acetate in a novel sustained-release delivery system","volume":"61","author":"Sartor","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.cpt.2024.10.001_bib46","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.eursup.2006.08.006","article-title":"Eligard\u00ae 6: a new form of treatment for prostate cancer","volume":"5","author":"Sartor","year":"2006","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.cpt.2024.10.001_bib47","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jconrel.2023.04.006","article-title":"HDACIs and TKIs combinations and their liposomal delivery for cancer treatment","volume":"358","author":"Schelker","year":"2023","journal-title":"J Contr Release"},{"key":"10.1016\/j.cpt.2024.10.001_bib48","article-title":"Nanoparticles in cancer diagnosis and treatment: progress, challenges, and opportunities","volume":"95","author":"Rashidi","year":"2024","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.cpt.2024.10.001_bib49","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/bcp.12260","article-title":"Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment","volume":"77","author":"Venkatakrishnan","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cpt.2024.10.001_bib50","series-title":"Silver spring: FDA","year":"2024"},{"key":"10.1016\/j.cpt.2024.10.001_bib51","article-title":"Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study","volume":"371","author":"Hwang","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.cpt.2024.10.001_bib52","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S1470-2045(15)00363-0","article-title":"Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial","volume":"16","author":"Place","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib53","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","article-title":"Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial","volume":"30","author":"Socinski","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib54","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1200\/JCO.1998.16.2.683","article-title":"Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group","volume":"16","author":"Stewart","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib55","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1081\/CNV-100104284","article-title":"Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma: a randomized trial of pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine","volume":"19","author":"Osoba","year":"2001","journal-title":"Cancer Invest"},{"key":"10.1016\/j.cpt.2024.10.001_bib56","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/annonc\/mdg287","article-title":"Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma","volume":"14","author":"Dimopoulos","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib57","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/cncr.21662","article-title":"Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial","volume":"106","author":"Rifkin","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.cpt.2024.10.001_bib58","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib59","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/cncr.23326","article-title":"Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide\/lenalidomide therapy","volume":"112","author":"Sonneveld","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.cpt.2024.10.001_bib60","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/cncr.30026","article-title":"Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma","volume":"122","author":"Orlowski","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.cpt.2024.10.001_bib61","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1200\/JCO.2004.08.157","article-title":"Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer","volume":"22","author":"Keller","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib62","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib63","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1200\/JCO.2008.20.5013","volume":"27","author":"Sparano","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib64","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10549-016-4033-3","article-title":"A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study","volume":"161","author":"Harbeck","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cpt.2024.10.001_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","article-title":"Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer","volume":"95","author":"Gordon","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib66","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib67","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1093\/annonc\/mdr001","article-title":"Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study","volume":"22","author":"Kurtz","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib68","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2010.33.8566","article-title":"Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial","volume":"29","author":"Pignata","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib69","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2011.04.019","article-title":"Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial","volume":"122","author":"Joly","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib70","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/annonc\/mdr583","article-title":"Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial","volume":"23","author":"Brundage","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib71","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/annonc\/mdr441","article-title":"Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial","volume":"23","author":"Gladieff","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib72","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.2012.307","article-title":"Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients","volume":"107","author":"Wagner","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cpt.2024.10.001_bib73","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ejca.2014.11.017","article-title":"Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial","volume":"51","author":"Mahner","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cpt.2024.10.001_bib74","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S1470-2045(20)30142-X","article-title":"Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial","volume":"21","author":"Pfisterer","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpt.2024.10.001_bib75","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s12010-015-1917-3","article-title":"A comprehensive review on L-asparaginase and its applications","volume":"178","author":"Batool","year":"2016","journal-title":"Appl Biochem Biotechnol"},{"key":"10.1016\/j.cpt.2024.10.001_bib76","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2014.12.030","article-title":"Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications","volume":"200","author":"Wicki","year":"2015","journal-title":"J Contr Release"},{"key":"10.1016\/j.cpt.2024.10.001_bib77","doi-asserted-by":"crossref","first-page":"853","DOI":"10.4103\/0973-1482.139267","article-title":"An overview of doxorubicin formulations in cancer therapy","volume":"10","author":"Rivankar","year":"2014","journal-title":"J Cancer Res Therapeut"},{"key":"10.1016\/j.cpt.2024.10.001_bib78","first-page":"131","article-title":"Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer","volume":"10","author":"Franco","year":"2018","journal-title":"Breast Cancer"},{"key":"10.1016\/j.cpt.2024.10.001_bib79","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/17474086.2017.1369400","article-title":"CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?","volume":"10","author":"Brunetti","year":"2017","journal-title":"Expert Rev Hematol"}],"container-title":["Cancer Pathogenesis and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713224000867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713224000867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:51:24Z","timestamp":1778935884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949713224000867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2949713224000867"],"URL":"https:\/\/doi.org\/10.1016\/j.cpt.2024.10.001","relation":{},"ISSN":["2949-7132"],"issn-type":[{"value":"2949-7132","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overview of randomized phase III clinical trials of cancer nanomedicines","name":"articletitle","label":"Article Title"},{"value":"Cancer Pathogenesis and Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpt.2024.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of Chinese Medical Association (CMA).","name":"copyright","label":"Copyright"}]}}